002390.KS
HANDOK Inc. [002390.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002390.KS Stock Summary
Top 10 Correlated ETFs
002390.KS
Top 10 Correlated Stocks
002390.KS
In the News
002390.KS Financial details
Company Rating
Neutral
Market Cap
185.12B
Income
-28.84B
Revenue
522.74B
Book val./share
24610.83
Cash/share
1457.11
Dividend
-
Dividend %
-
Employees
935
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
-34.5
Forward P/E
-
PEG
0.93
P/S
0.37
P/B
0.54
P/C
9.06
P/FCF
8.44
Quick Ratio
0.85
Current Ratio
1.18
Debt / Equity
0.88
LT Debt / Equity
0.36
-
-
EPS (TTM)
-2.1K
EPS next Y
-
EPS next Q
-
EPS this Y
-369.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
2.02%
Revenue Q/Q
-0.51%
EPS Q/Q
397.89%
-
-
-
-
SMA20
-6.4%
SMA50
-3.39%
SMA100
4.69%
Inst Own
-
Inst Trans
-
ROA
-1%
ROE
-2%
ROC
0.07%
Gross Margin
33%
Oper. Margin
7%
Profit Margin
-1%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
11480.0-16300.0
52W High
-19.02%
52W Low
+14.98%
RSI
39
Rel Volume
0.46
Avg Volume
21.27K
Volume
9.69K
Perf Week
-4.35%
Perf Month
-4.35%
Perf Quarter
10.92%
Perf Half Y
6.45%
-
-
-
-
Beta
0.713
-
-
Volatility
208.86%, 467.15%
Prev Close
-0.38%
Price
13200
Change
1.62%
002390.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 34.45K | 36.57K | 37.59K | 39.49K | 37.96K | |
| Net income per share | 2.54K | 1.96K | 239.28 | 775.88 | -2.09K | |
| Operating cash flow per share | 640.78 | 1.77K | 2.7K | 2.22K | 2.61K | |
| Free cash flow per share | -1.25K | 121.6 | -452.43 | -960.06 | 711.76 | |
| Cash per share | 2.22K | 2.45K | 2.57K | 2.89K | 1.46K | |
| Book value per share | 24.82K | 27.69K | 27.89K | 27.58K | 24.6K | |
| Tangible book value per share | 18.03K | 21.05K | 22K | 21.72K | 18.72K | |
| Share holders equity per share | 24.82K | 27.69K | 27.89K | 27.58K | 24.6K | |
| Interest debt per share | 16.16K | 17.48K | 19.18K | 22.26K | 22.72K | |
| Market cap | 311B | 458.53B | 313.95B | 232.02B | 203.38B | |
| Enterprise value | 508.31B | 668.82B | 541.9B | 493.46B | 486.83B | |
| P/E ratio | 8.9 | 17.01 | 95.28 | 21.72 | -7.06 | |
| Price to sales ratio | 0.66 | 0.91 | 0.61 | 0.43 | 0.39 | |
| POCF ratio | 35.35 | 18.84 | 8.43 | 7.6 | 5.65 | |
| PFCF ratio | -18.05 | 273.84 | -50.39 | -17.55 | 20.75 | |
| P/B Ratio | 0.91 | 1.2 | 0.82 | 0.61 | 0.6 | |
| PTB ratio | 0.91 | 1.2 | 0.82 | 0.61 | 0.6 | |
| EV to sales | 1.07 | 1.33 | 1.05 | 0.91 | 0.93 | |
| Enterprise value over EBITDA | 6.44 | 9.64 | 13.89 | 11.97 | 13.88 | |
| EV to operating cash flow | 57.77 | 27.48 | 14.56 | 16.17 | 13.53 | |
| EV to free cash flow | -29.51 | 399.43 | -86.99 | -37.33 | 49.67 | |
| Earnings yield | 0.11 | 0.06 | 0.01 | 0.05 | -0.14 | |
| Free cash flow yield | -0.06 | 0 | -0.02 | -0.06 | 0.05 | |
| Debt to equity | 0.63 | 0.61 | 0.67 | 0.79 | 0.88 | |
| Debt to assets | 0.29 | 0.29 | 0.31 | 0.34 | 0.38 | |
| Net debt to EBITDA | 2.5 | 3.03 | 5.84 | 6.34 | 8.08 | |
| Current ratio | 1.16 | 1.44 | 1.17 | 1.31 | 0.98 | |
| Interest coverage | 8.66 | 7.09 | 3.06 | 2.37 | 0.91 | |
| Income quality | 0.18 | 0.58 | 7.81 | 4.17 | -1.25 | |
| Dividend Yield | 0.02 | 0.01 | 0.01 | 0.02 | 0.03 | |
| Payout ratio | 0.18 | 0.14 | 1.25 | 0.45 | -0.19 | |
| Sales general and administrative to revenue | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 | |
| Research and developement to revenue | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 | |
| Intangibles to total assets | 0.13 | 0.11 | 0.1 | 0.09 | 0.1 | |
| Capex to operating cash flow | -2.96 | -0.93 | -1.17 | -1.43 | -0.73 | |
| Capex to revenue | -0.06 | -0.05 | -0.08 | -0.08 | -0.05 | |
| Capex to depreciation | -1.21 | -1.06 | -2.03 | -2.01 | -1.16 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 37.69K | 34.93K | 12.25K | 21.94K | 34.02K | |
| ROIC | 0.07 | 0.05 | 0.02 | 0.04 | 0 | |
| Return on tangible assets | 0.05 | 0.04 | 0 | 0.01 | -0.04 | |
| Graham Net | -13.78K | -14.81K | -16.39K | -17.2K | -18.64K | |
| Working capital | 41.72B | 100.53B | 47.74B | 83.24B | -6.18B | |
| Tangible asset value | 247.58B | 289.87B | 302.9B | 299.12B | 257.71B | |
| Net current asset value | -95.07B | -108.86B | -132.04B | -135.08B | -154.42B | |
| Invested capital | 0.63 | 0.61 | 0.67 | 0.79 | 0.88 | |
| Average receivables | 177.06B | 196.81B | 207.97B | 213.82B | 194.74B | |
| Average payables | 90.6B | 92.47B | 93.46B | 100.69B | 95.3B | |
| Average inventory | 85.85B | 89.22B | 83.92B | 88.28B | 93.46B | |
| Days sales outstanding | 141.59 | 152.3 | 145.11 | 148.92 | 117.05 | |
| Days payables outstanding | 107.84 | 102.61 | 96.62 | 107.22 | 80.5 | |
| Days of inventory on hand | 112.59 | 91.17 | 87.68 | 91.2 | 92.84 | |
| Receivables turnover | 2.58 | 2.4 | 2.52 | 2.45 | 3.12 | |
| Payables turnover | 3.38 | 3.56 | 3.78 | 3.4 | 4.53 | |
| Inventory turnover | 3.24 | 4 | 4.16 | 4 | 3.93 | |
| ROE | 0.1 | 0.07 | 0.01 | 0.03 | -0.09 | |
| Capex per share | -1.9K | -1.65K | -3.16K | -3.18K | -1.9K |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 9.88K | 9.33K | 10.21K | 9.24K | 9.2K | |
| Net income per share | 574.05 | -319.43 | -441.97 | -223.17 | -1.11K | |
| Operating cash flow per share | 904.57 | 2.78K | -676.64 | 953.87 | -441.48 | |
| Free cash flow per share | 42.3 | 2.3K | -1.26K | 586.85 | -921.39 | |
| Cash per share | 2.9K | 4K | 1.63K | 2.7K | 1.46K | |
| Book value per share | 27.6K | 26.97K | 26.37K | 26.14K | 24.61K | |
| Tangible book value per share | 21.73K | 21K | 20.45K | 20.25K | 18.72K | |
| Share holders equity per share | 27.6K | 26.97K | 26.37K | 26.14K | 24.61K | |
| Interest debt per share | 21.87K | 21.76K | 21.44K | 22.35K | 22K | |
| Market cap | 231.92B | 207.14B | 196.41B | 179.06B | 203.29B | |
| Enterprise value | 493.36B | 451.39B | 468.96B | 453.87B | 486.74B | |
| P/E ratio | 7.34 | -11.78 | -8.07 | -14.57 | -3.32 | |
| Price to sales ratio | 1.71 | 1.61 | 1.4 | 1.41 | 1.61 | |
| POCF ratio | 18.63 | 5.42 | -21.09 | 13.64 | -33.46 | |
| PFCF ratio | 398.31 | 6.53 | -11.34 | 22.17 | -16.03 | |
| P/B Ratio | 0.61 | 0.56 | 0.54 | 0.5 | 0.6 | |
| PTB ratio | 0.61 | 0.56 | 0.54 | 0.5 | 0.6 | |
| EV to sales | 3.63 | 3.52 | 3.34 | 3.57 | 3.85 | |
| Enterprise value over EBITDA | 16.36 | 55.86 | 89.72 | 56.01 | 137.98 | |
| EV to operating cash flow | 39.63 | 11.8 | -50.36 | 34.57 | -80.1 | |
| EV to free cash flow | 847.33 | 14.23 | -27.08 | 56.19 | -38.38 | |
| Earnings yield | 0.03 | -0.02 | -0.03 | -0.02 | -0.08 | |
| Free cash flow yield | 0 | 0.15 | -0.09 | 0.05 | -0.06 | |
| Debt to equity | 0.79 | 0.8 | 0.8 | 0.84 | 0.88 | |
| Debt to assets | 0.34 | 0.34 | 0.35 | 0.36 | 0.38 | |
| Net debt to EBITDA | 8.67 | 30.23 | 52.14 | 33.91 | 80.35 | |
| Current ratio | 1.31 | 1.27 | 1.17 | 1.18 | 0.98 | |
| Interest coverage | 8.9 | 0.76 | 1.5 | 1.32 | -0.59 | |
| Income quality | 1.2 | -7.4 | 1.28 | -3.07 | 0.4 | |
| Dividend Yield | 0 | 0 | 0.03 | 0 | 0 | |
| Payout ratio | 0 | 0 | -0.91 | 0 | 0 | |
| Sales general and administrative to revenue | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | |
| Research and developement to revenue | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 | |
| Intangibles to total assets | 0.09 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Capex to operating cash flow | -0.95 | -0.17 | 0.86 | -0.38 | 1.09 | |
| Capex to revenue | -0.09 | -0.05 | -0.06 | -0.04 | -0.05 | |
| Capex to depreciation | -2.17 | -1.15 | -1.42 | -0.93 | -1.15 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 18.88K | 13.92K | 16.19K | 11.46K | 24.8K | |
| ROIC | 0.03 | 0 | 0.01 | 0.01 | 0 | |
| Return on tangible assets | 0.01 | -0.01 | -0.01 | 0 | -0.02 | |
| Graham Net | -17.2K | -17.33K | -17.86K | -17.14K | -18.65K | |
| Working capital | 83.24B | 75.04B | 47.56B | 51.44B | -6.18B | |
| Tangible asset value | 299.12B | 289.02B | 281.51B | 278.68B | 257.71B | |
| Net current asset value | -135.08B | -141.8B | -145.27B | -137.94B | -154.42B | |
| Invested capital | 0.79 | 0.8 | 0.8 | 0.84 | 0.88 | |
| Average receivables | 226.37B | 215.26B | 214.42B | 211.52B | 185.25B | |
| Average payables | 115.42B | 112.49B | 113.1B | 103.94B | 89.93B | |
| Average inventory | 95.91B | 90.76B | 89.95B | 92.6B | 94.41B | |
| Days sales outstanding | 146.79 | 146.29 | 140.99 | 143.5 | 119.19 | |
| Days payables outstanding | 105.72 | 120.29 | 105.25 | 103.13 | 78.64 | |
| Days of inventory on hand | 89.93 | 92.12 | 86.98 | 99.34 | 90.7 | |
| Receivables turnover | 0.61 | 0.62 | 0.64 | 0.63 | 0.76 | |
| Payables turnover | 0.85 | 0.75 | 0.86 | 0.87 | 1.14 | |
| Inventory turnover | 1 | 0.98 | 1.03 | 0.91 | 0.99 | |
| ROE | 0.02 | -0.01 | -0.02 | -0.01 | -0.05 | |
| Capex per share | -862.26 | -473.22 | -581.71 | -367.02 | -479.91 |
002390.KS Frequently Asked Questions
What is HANDOK Inc. stock symbol ?
HANDOK Inc. is a KR stock and trading under the symbol 002390.KS
What is HANDOK Inc. stock quote today ?
HANDOK Inc. stock price is $13200 today.
Is HANDOK Inc. stock public?
Yes, HANDOK Inc. is a publicly traded company.
Company Profile
- Volume Average 21.27K
- Market Capitalization 185.12B
- Employee 935
- CEO Mr. Young-Jin Kim M.B.A.
- Headquarters Seoul,KR
- IPO Date 2000-01-04
-
Website
https://www.handok.co.kr 
Handok Inc. operates as an integrated pharmaceutical company. The company provides ETC and OTC drugs, medical devices, and in-vitro diagnostics instruments and devices. It focuses on various therapeutic areas, such as oncology, diabetes and metabolic disorders, CNS orphan diseases, eye disorders, and other disease areas. The company also offers healthcare products comprising food supplements under the NatureSet and Culturelle brands; food and beverages; and medical nutrition products. Handok Inc. has a strategic collaboration agreement with AUM Biosciences Pte. Ltd. and CMG Pharmaceutical Co. Ltd. for the development, manufacturing, and commercialization of CHC2014, a pan-TRK inhibitor for cancer treatment. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is based in Seoul, South Korea.
